Malignes Melanom

  • Constantin E. Orfanos
  • Claus Garbe

Zusammenfassung

Das maligne Melanom ist ein invasiver maligner Tumor, der von den Melanozyten ausgeht. Mehr als 90% der Tumoren entwickeln sich. primär an der Haut; entsprechend dem Vorkommen von Melanozyten können maligne Melanome auch an der Retina des Auges, an Schleimhäuten (z. B. Nasenschleimhaut, Vagina), am Innenohr, an den Meningen etc. entstehen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Ausgewählte Literatur

1. Prognose und Übersichten zur Therapie und Nachsorge in verschiedenen Stadien

  1. Ames FC, Balch CM, Reintgen D (1992) Local recurrences and their management. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ (eds) Cutaneous melanoma. Lippincott, Philadelphia, pp 287–294Google Scholar
  2. Braun-Falco O, Landthaler M, Hölzel D, Konz B, Schmoeckel C (1986) Therapie und Prognose maligner Melanome der Haut. Dt Med Wochenschr 111: 1750–1756Google Scholar
  3. D’Hoedt B, Stroebel W, Stutte H, Rassner G (1990) Nachsorge des malignen Melanoms an der Tübinger Hautklinik. In: Orfanos CE, Garbe C (Hrsg) Das maligne Melanom der Haut. Zuckschwerdt, München, S 304–311Google Scholar
  4. Garbe C (1993) Schwangerschaft, Hormonpräparate und malignes Melanom. Hautarzt 44: 347–352PubMedGoogle Scholar
  5. Garbe C, Orfanos CE (1992) Epidemiology of malignant melanoma in Central Europe. Risk Factors and prognostic predictors. Pigment Cell Res 5 (Supp12): 285–294Google Scholar
  6. Garbe C, Orfanos CE (1993) Malignes Melanom der Haut. In: Seeber S, Schütte J (Hrsg.) Therapiekonzepte Onkologie. Berlin: Springer, S 229–250Google Scholar
  7. Garbe C, Stadler R, Orfanos CE (1986) Prognoseorientierte Therapie bei malignem Melanom. Hautarzt 37: 365–372PubMedGoogle Scholar
  8. Garbe C, Büttner P, Bertz J et al. (1990) Die Prognose des primären malignen Melanoms–eine multizentrische Studie an 5093 Patienten. In: Orfanos CE, Garbe C (Hrsg) Das maligne Melanom der Haut. Zuckschwerdt, München, S 41–59Google Scholar
  9. Garbe C, Taud W, Karg Ch, Orfanos CE (1990) Nachsorge des metastasierenden malignen Melanoms. In: Orfanos CE, Garbe C (Hrsg) Das maligne Melanom der Haut. Zuckschwerdt, München, S 316–324Google Scholar
  10. Häffner AC, Garbe C, Büttner P et al. (1992) The prognosis of primary and metastasizing melanoma. An evaluation of the TNM classification in 2,495 patients and proposals for their revision. Br J Cancer 66: 856–861PubMedGoogle Scholar
  11. Ho VC, Sober AJ (1990) Therapy for cutaneous melanoma: an update. J Am Acad Dermatol 22: 159–176PubMedGoogle Scholar
  12. Hundeiker M, Drepper H (1987) Therapie der mali- gnen Melanome. Dt Med Wochenschr 112: 553–555Google Scholar
  13. Illig L (1985) Moderne Mehrstufentherapie des mali- gnen Melanoms der Haut. Med Welt 36: 1024–1080Google Scholar
  14. Ketcham AS, Moffat FL, Balch CM (1992) Classification and staging. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ (eds) Cutaneous melanoma. Lippincott, Philadelphia, pp 165–187Google Scholar
  15. Landthaler M, Braun-Falco O (1989) Zur Therapie des malignen Melanoms im Stadium I. Offene Fragen und Empfehlungen. Onkologie 12: 269–272Google Scholar
  16. Legha SS (1989) Current therapy for malignant melanoma. Semin Oncol 16: 34–44PubMedGoogle Scholar
  17. Orfanos CE, Jung HG, Rassner G et al. (1994) Stellungnahme und Empfehlungen der Kommission Malignes Melanom der Deutschen Dermatologischen Gesellschaft zur Diagnostik, Behandlung und Nachsorge des malignen Melanoms der Haut–Stand 1993/94. Hautarzt 45: 285–291PubMedGoogle Scholar
  18. Polk HC Jr (1989) Individual treatment for malignant melanoma. J Surg Oncol 40: 46–48PubMedGoogle Scholar
  19. Singletary SE, Balch CM (1992) Recurrent regional metastases and their management. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ (eds) Cutaneous melanoma. Lippincott, Philadelphia, pp 427–435gGoogle Scholar

Primäre Exzision

  1. Ackerman AB, Scheiner AM (1983) How wide and deep is wide and deep enough? A critique of surgical practice in excision of primary cutaenous malignant melanoma. Human Pathol 14: 743–744Google Scholar
  2. Aitken DR, Clausen K, Klein JP et al. (1983) The extent of primary melanoma excision. A reevaluation–how wide is wide? Ann Surg 198: 634–641PubMedGoogle Scholar
  3. Breslow A, Macht SD (1977) Optimal size of resection margin for thin cutaneous melanoma. Surgery Gynecol Obstet 145: 691–692Google Scholar
  4. Cascinelli N, van der Esch EP, Breslow A, Morabito A, Butalino R (1980) Stage I melanoma of the skin: the problem of resection margin. Eur J Cancer 16: 1079–1085Google Scholar
  5. Day CL Jr, Mihm MC Jr, Sober AJ, Fitzpatrick TB, Malt RA (1982) Narrower margins for clinical stage I malignant melanoma. N Engl J Med 306: 479–482PubMedGoogle Scholar
  6. Garbe C, Stadler R, Orfanos CE (1989) Lokalrezidive und Metastasierung bei dünnen malignen Melanomen (1 mm). Hautarzt 40: 337–343PubMedGoogle Scholar
  7. Kelly JW, Sagebiel RW, Calderon W, Murillo L, Dakin RL, Blois MS (1984) The frequency of local recurrence and microsatellites as a guide to reexcision margins for cutaneous malignant melanoma. Ann Surg 200: 759–763PubMedGoogle Scholar
  8. Landthaler M, Braun-Falco O, Hölzel D, Konz B, Schubert-Fritsche G (1990) Der Sicherheitsabstand bei der primären operativen Versorgung des malignen Melanoms. In: Orfanos CE, Garbe C (Hrsg.) Das maligne Melanom der Haut. Zuckschwerdt, München, S 209–213Google Scholar
  9. Petres J, Lohrisch I, Rezazada M. Azim (1990) Operative Therapie des malignen Melanoms. In: Orfanos CE, Garbe C (Hrsg) Das maligne Melanom der Haut. Zuckschwerdt, München, S 191–208Google Scholar
  10. Schmoeckel C, Bockelbrink A, Bockelbrink H, Braun-Falco O (1983) Low-and high-risk malignant melanoma. III. Prognostic significance of the resection margin. Eur J Cancer Clin Oncol 19: 245–249Google Scholar
  11. Urist MM, Balch CM, Soong SJ, Shaw HM, Milton GW, Maddox WA (1985) The influence of surgical margins and prognostic factors predicting the risk of local recurrence in 3445 patients with primary cutaneous melanoma. Cancer 55: 1398–1402PubMedGoogle Scholar
  12. Veronesi U, Cascinelli N, Adamus J et al. (1988) Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med 318: 1159–1162PubMedGoogle Scholar

Elektive Lymphadenektomie

  1. Balch CM (1980) Surgical management of regional lymph nodes in cutaneous melanoma. J Am Acad Dermatol 3: 511–524PubMedGoogle Scholar
  2. Balch CM (1988) The role of elective lymph node dissection in melanoma: Rationale, results, and controversies. J Clin Oncol 6: 163–172PubMedGoogle Scholar
  3. Balch CM, Soong SJ, Milton GW et al. (1982) A comparison of prognostic factors and surgical results in 1786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg 196: 677–684Google Scholar
  4. Balch CM, Milton GW, Cascinelli N, Sim HF (1992) Elective lymph node dissection: pros and cons. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ (eds) Cutaneous melanoma. Lippincott, Philadelphia, pp 345–366Google Scholar
  5. Drepper H, Bieß B, Bröcker EB et al. (1990) Ergebnisse einer vergleichenden Studie zur elektiven Lymphknotendissektion. In: Orfanos CE, Garbe C (Hrsg) Das maligne Melanom der Haut. Zuckschwerdt, München, S 214–221Google Scholar
  6. Drepper H, Köhler CO, Bastian B et al. (1993) Benefit of elective node dissection in subgroups of melanoma patients–results of a multicenter study in 3616 patients. Cancer 72: 741–749PubMedGoogle Scholar
  7. Milton GW, Shaw HM, McCarthy WH, Pearson L, Balch CM, Soong SJ (1982) Prophylactic lymph node dissection in clinical stage I cutaneous malignant melanoma: Results of surgical treatment in 1319 patients. Br J Surg 69: 108–111PubMedGoogle Scholar
  8. Reintgen DS, Cox EB, McCarthy KS Jr, Vollmer RT, Steigler HF (1983) Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma. Ann Surg 198: 379–385PubMedGoogle Scholar
  9. Veronesi U, Adamus J, Bandiera DC et al. (1977) Inefficacy of immediate node dissection in stage I melanoma of the limbs. N Engl J Med 297: 627–630PubMedGoogle Scholar
  10. Veronesi U, Adamus J, Bandiera DC et al. (1982) Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 49: 2420–2430PubMedGoogle Scholar

Adjuvante Therapie

  1. Balch CM, Hersey P (1985) Current status of adjuvant therapy. In: Balch CM, Milton GW (eds) Cutaneous melanoma. Clinical management and treatment results worldwide. Lippincott, Philadelphia, pp 197–218Google Scholar
  2. Beiteke U, Ruppert P, Garbe C et al. (1993) Adjuvante Therapie des primären malignen Melanoms mit natürlichem humanen Interferon-beta. Signifikanter Überlebensvorteil bei 96 behandelten Patienten im Vergleich zu 288 unbehandelten Symptomenzwillingen. Hautarzt 44: 365–371PubMedGoogle Scholar
  3. Burg G, Lechner W, Müller W (1990) Adjuvante Nachbehandlung beim malignen Melanom. In Orfanos CE, Garbe C (Hrsg) Das maligne Melanom der Haut. Zuckschwerdt, München, S 312–315Google Scholar
  4. Czarnetzki BM, Aragon V, Bröcker EB et al. (1986) Adjuvante Polychemotherapie zusätzlich zur radikalen operativen Behandlung regionaler Lymphknotenmetastasen beim malignen Melanom. Dt Med Wochenschr 11: 732–736Google Scholar
  5. Elsasser-Beile U, Garbe C, Stadler R et al. (1989) Adjuvante Therapie mit rekombiniertem Interferon alpha-2a beim metastasierten malignen Melanom. Hautarzt 40: 266–270PubMedGoogle Scholar
  6. Fiedler H, Hetschko I, Wohirab Wet al. (1990) Ergebnisse einer randomisierten Polychemotherapiestudie beim malignen Melanom. Hautarzt 41: 369–374PubMedGoogle Scholar
  7. Garbe C, Guenther-Eymann K, Stadler R et al. (1988) Adjuvante Chemotherapie des malignen Melanoms mit DTIC. Wirkungslosigkeit im Stadium I, mögliche Verbesserung der Überlebensprognose im Stadium IIb. Hautarzt 39: 205–212PubMedGoogle Scholar
  8. Koh HK, Sober AJ, Harmon DC et al. (1985) Adjuvant therapy of cutaneous malignant melanoma: a critical review. Med Pediatr Oncol 13: 244–260PubMedGoogle Scholar
  9. Lejeune FJ (1987) Phase III adjuvant studies in operable malignant melanoma (review). Anticancer Res 7: 701–706PubMedGoogle Scholar
  10. Lejeune FJ, Macher E, Kleeberg U et al. (1988) An assessment of DTIC versus levamisole or placebo in the treatment of high risk stage I patients after surgical removal of a primary melanoma of the skin. A phase III adjuvant study. EORTC protocol 18761. Eur J Cancer Clin Oncol [Suppl 2] 24: 81–90Google Scholar
  11. Veronesi U, Adamus J, Aubert C et al. (1982) A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. New Engl J Med 307: 913–916PubMedGoogle Scholar

Strahlentherapie

  1. Bentzen SM, Overgaard J, Thames HD, Overgaard M, Vejby-Hansen P, von-der-Maase H, Meder J (1989) Clinical radiobiology of malignant melanoma. Radiother Oncol 16: 169–182PubMedGoogle Scholar
  2. Harwood AR, Cummings BJ (1981) Radiotherapy for malignant melanoma: a re-appraisal. Cancer Treat Rev 8: 271PubMedGoogle Scholar
  3. Harwood AR, Dancuart F, Fitzpatrick PJ (1981) Radiotherapy in nonlentiginous melanoma of the head and neck. Cancer 48: 2599PubMedGoogle Scholar
  4. Overgaard J (1985) A randomized study comparing two high dose per fraction radiation schedules in recurrent or metastatic malignant melanoma. Int J Radiat Oncol Biol Phys 11: 1837–1839PubMedGoogle Scholar
  5. Overgaard J (1986) The role of radiotherapy in recurrent and metastatic malignant melanoma: a clinical radiobiological study. Int J Radiat Oncol Biol Phys 12: 867PubMedGoogle Scholar
  6. Panizzon R (1986) Die Radiotherapie des malignen Melanoms der Haut–eine Renaissance? Hautarzt 37: 481–484PubMedGoogle Scholar
  7. Panizzon R, Alber R, Schnyder UW (1990) Die dermatologische Radiotherapie des Melanoms der Haut mit besonderer Berücksichtigung des Lentigomaligna-Melanoms. In: Orfanos CE, Garbe C (Hrsg) Das maligne Melanom der Haut. Zuckschwerdt, München, S 232–235Google Scholar

Chemotherapie

  1. Ahmann DL, Creagan ET, Hahn RG et al. (1989) Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 63: 224–227PubMedGoogle Scholar
  2. Ahn SS, Giuliano A, Kaiser L et al. (1983) The limited role of BOLD chemotherapy for disseminated malignant melanoma. Proc Am Soc Clin Oncol 2: 228, C-893Google Scholar
  3. Bajetta E, Rovej R, Buzzoni R et al. (1982) Treatment of advanced malignant melanoma with vinblastine, bleomycin, and cisplatin. Cancer Treat Rep 66: 1299–1302PubMedGoogle Scholar
  4. Bellet RE, Mastrangelo MJ, Berd D et al. (1979) Chemotherapy of metastatic malignant melanoma. In: Clark WH Jr, Goldmann LI, Mastrangelo MJ (eds) Human malignant melanoma. Grune & Stratton, New York, pp 325–354Google Scholar
  5. Beretta G, Bajetta E, Bonadonna G et al. (1973) Poli-chemioterapia con 5-(3,3 dimetil-1-triazeno)-imidazole-4-carboxamide (DTIC; NSC-45388), 1,3-bis (2cloroetil)-1-nitrosourea (BCNU; NSC-409962) e vincristina (NSC-67574) nel melanoma in fase metastatizzata. Tumori 59: 239–248PubMedGoogle Scholar
  6. Cartei G, Ceschia T, Marsilio P et al. (1989) Effectiveness and toxicity of „BELD“ polychemotherapy in advanced malignant melanoma. Tumori 75: 229–232PubMedGoogle Scholar
  7. Carter RD, Krementz ET, Hill GJ et al. (1976) DTIC (NSC-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065). Cancer Treat Rep 60: 601–609PubMedGoogle Scholar
  8. Cohen SM, Greenspan EM, Ratner LH, Weiner MJ (1977) Combination chemotherapy of malignant melanoma with imidazole carboxamide, BCNU and vincristine. Cancer 39: 41–44Google Scholar
  9. Constanzi JJ, Vaitkevicius VK, Quagliana JM et al. (1975) Combination chemotherapy for disseminated malignant melanoma. Cancer 35: 342–346Google Scholar
  10. Constanzi JJ, Fletcher WS, Balcerzak SP et al. (1984) Combination chemotherapy plus levamisole in the treatment of disseminated malignant melanoma. Cancer 53: 833–836Google Scholar
  11. Creagan ET, Ahmann DL, Schutt AJ et al. (1982) Phase II study of the combination of vinblastine, bleomycin, and cisplatin in advanced malignant melanoma. Cancer Treat Rep 66: 567–569PubMedGoogle Scholar
  12. Del Prete SA, Maurer LH, O’Donnell J et al. (1984) Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 68: 1403–1405PubMedGoogle Scholar
  13. Einhorn LH, Burgess MA, Vallejos C et al. (1974) Prognostic correlations and response to treatment in advanced metastatic melanoma. Cancer Res 34: 1995–2004PubMedGoogle Scholar
  14. Garbe C (1993) Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. Melanoma Res 3: 291–299PubMedGoogle Scholar
  15. Garbe C, Drechsler S, Schroeder K et al. (1994) Dose comparison of 5 and 10 mg Tropisetron orally in the prophylaxis of dacarbazine-induced nausea and emesis. Semin Oncol 21: 12–16PubMedGoogle Scholar
  16. Gerner RE, Moore GE, Didolkar MS (1973) Chemotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and dactinomycin. Cancer 32: 756–760PubMedGoogle Scholar
  17. Gundersen S (1987) Dacarbacine, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma: a phase II study. Cancer Treat Rep 71: 997–999PubMedGoogle Scholar
  18. Halpern J, Catane R, Biran S et al. (1981) DTIC and actinomycin D with and without C. Parvum immunotherapy in advanced malignant melanoma. Tumori 67: 215–217PubMedGoogle Scholar
  19. Hill GJ, Krementz ET, Hill HZ (1984) Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group Protocols 7130, 7131, and 7131A). Cancer 53: 1299–1305PubMedGoogle Scholar
  20. Hochster H, Levin M, Speyer J et al. (1985) Single-dose dacarbazine and dactinomycin in advanced malignant melanoma. Cancer Treat Rep 69: 39–42PubMedGoogle Scholar
  21. Houghton AN, Legha S, Bajorin DF (1992) Chemotherapy for metastatic melanoma. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ (eds) Cutaneous melanoma. Lippincott, Philadelphia, pp 498–508Google Scholar
  22. Jacquillat C, Khayat D, Banzet P et al. (1990) Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma. Cancer Chemother Pharmacol 25: 263–266PubMedGoogle Scholar
  23. Johnson DH, Presant C, Einhorn L et al. (1985) Cisplatin, vinblastine, and bleomycin in the treatment of metastatic melanoma: a phase II study of the Southeastern Cancer Study Group. Cancer Treat Rep 69: 821–824PubMedGoogle Scholar
  24. Karg CH, Garbe C, Orfanos CE (1990) Chemotherapie des malignen Melanoms–Aktueller Stand. Hautarzt 41: 56–65PubMedGoogle Scholar
  25. Legha SS, Ring S, Papadopoulos N et al. (1989) A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine ( CVD) vor metastatic melanoma. Cancer 64: 2024–2029PubMedGoogle Scholar
  26. Luikart SD, Kennealey GT, Kirkwood JM (1984) Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol 2: 164–168PubMedGoogle Scholar
  27. McClay EF, Mastrangelo MJ, Bellet RE, Berd D (1987) Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 71: 465–469PubMedGoogle Scholar
  28. Nathanson L, Kaufman SD, Carey RW (1981) Vmblastine, infusion, bleomycin, and cis-dichlorodiammine-platinum chemotherapy in metastatic melanoma. Cancer 48: 1290–1294PubMedGoogle Scholar
  29. National Cancer Institute of Canada Melanoma Group (1984) Vinblastine, bleomycin, and cis-platinum for the treatment of metastatic malignant melanoma. J Clin Oncol 2: 131–134Google Scholar
  30. Orfanos CE, Garbe C, Karg CH (1990) Chemotherapie des malignen Melanoms. In: Orfanos CE, Garbe C (Hrsg) Das maligne Melanom der Haut. Zuckschwerdt, München, S 222–231Google Scholar
  31. Pectasides D, Yianniotis H, Alevizakos N et al. (1989) Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin. Br J Cancer 60: 627–629PubMedGoogle Scholar
  32. Richards JM, Gilewski TA, Ramming K et al. (1992) Effective chemotherapy for melanoma after treatment with interleukin-2. Cancer 69: 427–429PubMedGoogle Scholar
  33. Robidoux A, Gutterman JU, Bodey GP et al. (1982) Actinomycin-D plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide ( DTIC) with or without intravenous Corynebacterium parvum in metastatic malignant melanoma. Cancer 49: 2246–2251PubMedGoogle Scholar
  34. Rümke P, Dewit L (1987) Non-surgical treatment of melanoma. In: Veronesi U, Cascinelli N, Santinami M (eds) Cutaneous melanoma. Status of knowledge and future perspective. Academic Press, London, pp 63–97Google Scholar
  35. Saba HI, Cruse CW, Wells KE et al. (1992) Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: a University of South Florida and H. Lee Moffitt Melanoma Center Study. Ann Plast Surg 28: 65–69PubMedGoogle Scholar
  36. Samson MK, Baker LH, Talley RW et al. (1978) Phase I-II study of intermittent bolus administration of DTIC and actinomycin D in metastatic malignant melanoma. Cancer Treat Rep 62: 1223–1225PubMedGoogle Scholar
  37. Schröder K, Garbe C, Rinck G, Orfanos CE (1992) Einsatz von Tropisetron beim Zytostatika-induzierten Erbrechen. Erfahrungen an 20 Patienten mit malignem Melanom während der Polychemotherapie (BHD-Schema: BCNU, Hydroxyurea, Dacarbazin). Derm Monatsschr 178: 425–430Google Scholar
  38. Seigler HF, Lucas VS Jr, Pickett NJ et al. (1980) DTIC, CCNU, bleomycin and vincristine ( BOLD) in metastatic melanoma. Cancer 46: 2346–2348Google Scholar
  39. The Prudente Foundation Melanoma Study Group (1989) Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). Cancer 63: 1676–1680Google Scholar
  40. Verschraegen CF, Kleeberg UR, Mulder J et al. (1988) Combination of cisplatin, vindesine, and dacarbazine in advanced malignant melanoma. Cancer 62: 1061–1065PubMedGoogle Scholar
  41. Voigt H, Kleeberg UR (1986) Systemische Chemotherapie maligner Melanome. In: Voigt H, Kleeberg UR (Hrsg) Malignes Melanom. Springer, Berlin Heidelberg New York Tokyo, S 235–298Google Scholar
  42. York RM, Foltz AT (1988) Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma. Cancer 61: 2183–2186PubMedGoogle Scholar
  43. York RM, Lawson DH, McKay J (1983) Treatment of metastatic malignant melanoma with vinblastine, bleomycin by infusion and cisplatin. Cancer 52: 2220–2222PubMedGoogle Scholar
  44. Young DW, Lever RS, English JSC, Mackie RM (1985) The use of BELD combination therapy (bleomycin, vindesine, CCNU and DTIC) in advanced malignant melanoma. Cancer 55: 1879–1881Google Scholar

Immuntherapie

  1. Bajetta E, Negretti E, Giannotti B et al. (1990) Phase II study of interferon-alpha-2a and dacarbazine in advanced melanoma. Am J Clin Oncol 13: 405–409PubMedGoogle Scholar
  2. Breier S, Pensel R, Roffe C et al. (1990) High dose DTIC with recombinant human interferon alpha-2b (rhifn2b) for the treatment of metastatic malignant melanoma ( MMM ). Proc Annu Meet Am Soc Clin Oncol 9: A1090Google Scholar
  3. Demchak PA, Mier JW, Robert NJ et al. (1990) Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study. J Clin Oncol 9: 1821–1830Google Scholar
  4. Dillman RO, Oldham RK, Barth NM et al. (1990) Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: a National Biotherapy Study Group trial. J Natl Cancer Inst 82: 1345–1349PubMedGoogle Scholar
  5. Dummer R, Becker JC, Kalhammer U et al. (1991) Combined chemo-and immunotherapy using dacarbazine and continuous infusion of interleukin 2 in metastatic malignant melanoma. Results of a phase II clinical trial. Eur J Dermatol 1: 201–205Google Scholar
  6. Falkson CI, Falkson G, Falkson HC (1991) Improved results with the addition of recombinant interferon alpha-2b to dacarbazine in treatment of patients with metastatic malignant melanoma. J Clin Oncol 9: 1403–1408PubMedGoogle Scholar
  7. Flaherty LE, Redman BG, Chabot GG et al. (1990) A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma. Cancer 65: 2471–2477PubMedGoogle Scholar
  8. Garbe C (1994) Perspectives of cytokine treatment in malignant skin tumors. Recent Results Cancer Res (in press)Google Scholar
  9. Garbe C, Krasagakis K (1993) Effects of interferons and cytokines on melanoma cells. J Invest Dermatol 100: 239S - 244SPubMedGoogle Scholar
  10. Garbe C, Krasagakis K, Zouboulis C et al. (1990) Antitumor activities of interferon-alpha, -beta and -gamma on malignant melanoma cells in vitro. Changes of proliferation, melanin synthesis and immunophenotype. J Invest Dermatol 95: 231S - 237SPubMedGoogle Scholar
  11. Garbe C, Kreuser ED, Zouboulis CC et al. (1992) Combined Treatment of Metastatic Melanoma with Interferons and Cytotoxic Drugs. Semin Oncol 19 [Supp14]: 63–69PubMedGoogle Scholar
  12. Garbe C, Zouboulis CC, Krüger S et al. (1992) Kombination von Interferon-alpha mit Zytostatika: Erfolgversprechender Therapieansatz beim metastasierten Melanom. Hautarzt 43: 4–10Google Scholar
  13. Garbe C, Zouboulis CC, Stadler R et al. (1993) Prolongation of life in stage IV melanoma by combined treatment with IFN-a-2a and vindesine. Pigment Cell Res 6: 278Google Scholar
  14. Gundersen S, Flokkmann A (1989) Interferon in combination with vinblastine in advanced malignant melanoma. A phase I-II study. Cancer 64: 1617–1619Google Scholar
  15. Hamblin TJ, Davies B, Sadullah S et al. (1991) A phase II study of the treatment of metastatic malignant melanoma with a combination of dacarbazine, cisplatin, interleukin-2(IL-2) and alfa-interferon ( IFN ). Proc Annu Meet Am Soc Clin Oncol 10: A1029Google Scholar
  16. Hersey P, McLeod RC, Thomson DB (1989) Phase I/II study of tolerability and efficacy of recombinant interferon (Roferon) with dacarbazine (DTIC) in advanced malignant melanoma. J Interferon Res 9 [Supp12]: 118Google Scholar
  17. Keilholz U, Scheibenbogen C, Tilgen W et al. (1993) Interferon-a and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials. Cancer 72: 607–614Google Scholar
  18. Kellokumpu-Lehtinen P, Nordman E, Toivanen A (1989) Combined interferon and vinblastine treatment of advanced melanoma: Evaluation of the treatment results and the effects of treatment on immunological functions. Cancer Immunol Immunother 28: 213–217Google Scholar
  19. Kerr R, Pippen P, Mennel R, Jones S (1989) Treatment of metastatic malignant melanoma with a combination of interferon-alpha-2a (ifn-alpha-2a, Roferon) and dacarbazine ( DTIC ). Proc Annu Meet Am Soc Clin Oncol 8: A1122Google Scholar
  20. Legha SS (1986) Interferons in the treatment of malignant melanoma. A review of recent trials. Cancer 57: 1675–1677PubMedGoogle Scholar
  21. Legha S, Plager C, Ring S et al. (1992) A phase II study of biochemotherapy using interleukin-2 (IL-2) + Interferon alfa-2a (IFN) in combination with cisplatin (C) vinblastine (V) and DTIC ( D) in patients with metastatic melanoma. Proc Annu Meet Am Soc Clin Oncol 11: A1179Google Scholar
  22. Margolin K, Doroshow J, Akman S et al. (1990) Treatment (RX) of advanced melanoma with cis-diamminedichloroplatinum ( CDDP) and alpha interferon (alpha IFN ). Proc Annu Meet Am Soc Clin Oncol 9: A1074Google Scholar
  23. McLeod GRC, Thomson DB, Hersey P (1987) Recombinant interferon alpha 2 in advanced malignant melanoma. A phase I-II study in combination with DTIC. Int J Cancer [Suppl] 1: 31–35Google Scholar
  24. Meyskens FL Jr, Kopecky K, Samson M et al. (1990) Recombinant human interferon gamma: adverse effects in high-risk stage I and II cutaneous malignant melanoma (letter). J Natl Cancer Inst 82: 1071PubMedGoogle Scholar
  25. Mitchell MS, Kan-Mitchell J, Kempf RA et al. (1988) Active specific immuno-therapy for melanoma: phased trial of allogeneic lysates and a novel adjuvant. Cancer Res 48: 5883–5893PubMedGoogle Scholar
  26. Mitchell MS, Kempf RA, Harel W et al. (1988) Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 disseminated melanoma. J Clin Oncol 6: 409–424PubMedGoogle Scholar
  27. Mittelman A, Huberman M, Puccio C et al. (1990) A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma. Cancer 66: 664–669PubMedGoogle Scholar
  28. Mulder NH, Schraffordt-Koops H, Sleijfer DT et al. (1990) Dacarbacine and alpha-interferon for disseminated malignant melanoma. Proc Annu Meet Am Soc Clin Oncol 9: A1083Google Scholar
  29. Oratz R, Dugan M, Walsh C et al. (1989) Phase II trial of r-alpha 2b-interferon (IFN) and cisplatin (CDDP) in metastatic malignant melanoma ( MM ). Proc Annu Meet Am Soc Clin Oncol 8: A1123Google Scholar
  30. Richards J, Mehta N, Schroeder L, Dordal A (1992) Sequential chemotherapy/immunotherapy for metastatic melanoma. Proc Annu Meet Am Soc Clin Oncol 11: A1189Google Scholar
  31. Richards JM, Mehta N, Ramming K, Skosey P (1992) Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 10: 1338–1343PubMedGoogle Scholar
  32. Richner J, Cerny T, Joss RA et al. (1990) A phase II study of continuous sc alpha-2b interferon (IFN) combined with cisplatin (CDDP) in advanced malignant melanoma ( MM ). Proc Annu Meet Am Soc Clin Oncol 9: A1085Google Scholar
  33. Rosenberg SA, Lotze MT, Muul LM et al. (1985) Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. New Engl J Med 313: 1485–1492PubMedGoogle Scholar
  34. Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318–1321PubMedGoogle Scholar
  35. Rosenberg SA, Lotze MT, Mull LM et al. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889–897PubMedGoogle Scholar
  36. Rosenberg SA, Pachard BS, Aebersold PM et al. (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. New Engl J Med 319: 1676–1680PubMedGoogle Scholar
  37. Rosenberg SA, Lotze MT, Yang JC et al. (1989) Experience with the use of high dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210: 474–485PubMedGoogle Scholar
  38. Schuchter L, McGuire WP, Wohlganger J, Redden T (1989) Sequential treatment of metastatic melanoma with interferon-alpha (IFN) plus cis-platinum ( CDDP ). Proc Annu Meet Am Soc Clin Oncol 8: A1120Google Scholar
  39. Sertoli MR, Queirolo P, Bajetta E et al. (1992) Dacarbacine (DTIC) with or without recombinant interferon alpha-2a at different dosages in the treatment of stage IV melanoma patients. Prelimanary results of a randomized trial. Proc Annu Meet Am Soc Clin Oncol 11: A1185Google Scholar
  40. Smith KA, Green JA, Eccles JM (1992) Interferon alpha 2a and vindesine in the treatment of advanced malignant melanoma. Eur J Cancer 28: 438–441PubMedGoogle Scholar
  41. Stadler R, Garbe C (1990) Interferon-Therapie beim malignen Melanom. Z Hautkr 65: 504–507PubMedGoogle Scholar
  42. Stadler R, Garbe C (1991) Disseminated malignant melanoma. New therapeutic approaches. Int J Dermatol 30: 239–42Google Scholar
  43. Thomson D, Adena M, McLeod GRC et al. (1992) Interferona-2a (IFN) does not improve response or survival when added to dacarbazine (DTIC) in metastatic melanoma: Results of a multi-institutional Australian randomized trial QMP8704. Proc Annu Meet Am Soc Clin Oncol 11: A1177Google Scholar
  44. Tilgen W, Keilholz U, Zierott U et al. (1993) Metastasiertes Melanom: Neue Therapieformen. In: Braun-Falco O, Plewig G, Meurer M (Hrsg) Fortschritte der praktischen Dermatologie und Venerologie. Bd 13. Springer, Berlin Heidelberg New York Tokyo, S 167–178Google Scholar
  45. Wussow P von, Block B, Hartmann F, Deicher H (1988) Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 61: 1071–1074Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • Constantin E. Orfanos
    • 1
  • Claus Garbe
    • 1
  1. 1.Universitäts-Hautklinik und PoliklinikKlinikum Benjamin Franklin der Freien Universität BerlinBerlinDeutschland

Personalised recommendations